| Item Type | Name |
|
Academic Article
|
Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.
|
|
Academic Article
|
Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma.
|
|
Concept
|
Hodgkin Disease
|
|
Academic Article
|
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
|
|
Academic Article
|
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
|
|
Academic Article
|
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
|
|
Academic Article
|
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
|
|
Academic Article
|
[High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma].
|
|
Academic Article
|
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma.
|
|
Academic Article
|
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
|
|
Academic Article
|
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.
|
|
Academic Article
|
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
|
|
Academic Article
|
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
|
|
Academic Article
|
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
|
|
Academic Article
|
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
|
|
Academic Article
|
Hematopoietic stem cell transplantation for Hodgkin's disease.
|
|
Academic Article
|
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
|
|
Academic Article
|
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
|
|
Academic Article
|
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.
|
|
Academic Article
|
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
|
|
Academic Article
|
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
|
|
Academic Article
|
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
|
|
Academic Article
|
Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases.
|
|
Academic Article
|
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
|
|
Academic Article
|
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
|
|
Academic Article
|
Classical Hodgkin's lymphoma associated with Langerhans cell histiocytosis: multiagent chemotherapy resulted in histologic resolution of both the classical Hodgkin's lymphoma and Langerhans cell proliferation components.
|
|
Academic Article
|
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
|
|
Academic Article
|
Novel treatment strategies for aggressive non-Hodgkin's lymphoma.
|
|
Academic Article
|
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.
|
|
Academic Article
|
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
|
|
Academic Article
|
Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.
|
|
Academic Article
|
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
|
|
Academic Article
|
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.
|
|
Academic Article
|
Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.
|
|
Academic Article
|
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.
|
|
Academic Article
|
Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.
|
|
Academic Article
|
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
|
|
Academic Article
|
Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.
|
|
Academic Article
|
Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma
|
|
Academic Article
|
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes
|
|
Academic Article
|
Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma
|
|
Academic Article
|
Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial.
|
|
Academic Article
|
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
|
|
Academic Article
|
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
|
|
Academic Article
|
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
|
|
Academic Article
|
Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
|
|
Academic Article
|
Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma.
|
|
Academic Article
|
Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy.
|
|
Academic Article
|
ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.
|
|
Academic Article
|
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.
|
|
Academic Article
|
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?
|
|
Academic Article
|
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.
|
|
Academic Article
|
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.
|
|
Academic Article
|
Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission.
|
|
Academic Article
|
Can we cure refractory Hodgkin's lymphoma with transplantation?
|
|
Academic Article
|
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
|